EVOTEC SE (EVT.DE) Stock Price, Quote, News and Overview
FRA:EVT - Deutsche Boerse Ag - DE0005664809 - Common Stock - Currency: EUR
EVT.DE Quote, Performance and Key Statistics
FRA:EVT (3/7/2025, 7:00:00 PM)
6.595
-0.14 (-2.01%)
The current stock price of EVT.DE is 6.595 EUR. In the past month the price decreased by -24.02%. In the past year, price decreased by -49.41%.
EVT.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TN8.DE | THERMO FISHER SCIENTIFIC INC | 24.07 | 182.78B | ||
| DAP.DE | DANAHER CORP | 28.32 | 139.67B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 55.77 | 19.00B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 55.17 | 18.79B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 46.36 | 17.15B | ||
| SRT.DE | SARTORIUS AG | 37.17 | 13.75B | ||
| ILU.DE | ILLUMINA INC | 34.19 | 12.24B | ||
| ESF0.DE | EUROFINS SCIENTIFIC | 28.63 | 9.95B | ||
| ERF.PA | EUROFINS SCIENTIFIC | 28.53 | 9.91B | ||
| QIA.DE | QIAGEN N.V. | 18.07 | 7.89B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 25.09 | 3.74B | ||
| GXI.DE | GERRESHEIMER AG | 25.2 | 2.77B |
Related stock screener links
About EVT.DE
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 5,007 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
EVOTEC SE
Essener Bogen 7
Hamburg HAMBURG DE
Employees: 5022
Company Website: https://www.evotec.com/
Investor Relations: http://www.evotec.com/en/investor-relations/stock-information
Phone: 4940560810
EVOTEC SE / EVT.DE FAQ
What is the stock price of EVOTEC SE today?
The current stock price of EVT.DE is 6.595 EUR. The price decreased by -2.01% in the last trading session.
What is the ticker symbol for EVOTEC SE stock?
The exchange symbol of EVOTEC SE is EVT and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is EVT.DE stock listed?
EVT.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for EVOTEC SE stock?
15 analysts have analysed EVT.DE and the average price target is 12.06 EUR. This implies a price increase of 82.94% is expected in the next year compared to the current price of 6.595. Check the EVOTEC SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EVOTEC SE worth?
EVOTEC SE (EVT.DE) has a market capitalization of 2.34B EUR. This makes EVT.DE a Mid Cap stock.
How many employees does EVOTEC SE have?
EVOTEC SE (EVT.DE) currently has 5022 employees.
What are the support and resistance levels for EVOTEC SE (EVT.DE) stock?
EVOTEC SE (EVT.DE) has a support level at 6.58 and a resistance level at 8.09. Check the full technical report for a detailed analysis of EVT.DE support and resistance levels.
Is EVOTEC SE (EVT.DE) expected to grow?
The Revenue of EVOTEC SE (EVT.DE) is expected to grow by 2.9% in the next year. Check the estimates tab for more information on the EVT.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EVOTEC SE (EVT.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EVT.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EVT.DE, evaluating the profitability, health, valuation and growth aspects
- EVOTEC SE (EVT.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EVOTEC SE (EVT.DE) Sales and EPS estimates to see what analysts future expectations are.
- EVOTEC SE (EVT.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EVOTEC SE (EVT.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- EVOTEC SE (EVT.DE) Stock Chart to make your own analysis
- EVOTEC SE (EVT.DE) Latest news and press-releases to stay up to date.
Does EVOTEC SE (EVT.DE) stock pay dividends?
EVT.DE does not pay a dividend.
When does EVOTEC SE (EVT.DE) report earnings?
EVOTEC SE (EVT.DE) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of EVOTEC SE (EVT.DE)?
EVOTEC SE (EVT.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
EVT.DE Technical Analysis
EVT.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVT.DE. The financial health of EVT.DE is average, but there are quite some concerns on its profitability.
EVT.DE Financial Highlights
Over the last trailing twelve months EVT.DE reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -83.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.61% | ||
| ROE | -17.69% | ||
| Debt/Equity | 0.43 |
EVT.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to EVT.DE. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -46.13% and a revenue growth 2.9% for EVT.DE